[S01GX11, alcaftadine, The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Ziprasidone.]
[P02BB01, trichlorfon, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Ziprasidone.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Ziprasidone.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ziprasidone.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ziprasidone.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ziprasidone.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Ziprasidone.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulindac.]
[N05AL01, sulpiride, Ziprasidone may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Ziprasidone.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Ziprasidone.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Azapropazone.]
[N06DA01, tacrine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ziprasidone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Ziprasidone.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Ziprasidone.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ziprasidone.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Ziprasidone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Ziprasidone.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Ziprasidone.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Ziprasidone.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ziprasidone.]
[A04AD10, dronabinol, The risk or severity of adverse effects can be increased when Dronabinol is combined with Ziprasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ziprasidone.]
[L04AX02, thalidomide, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Ziprasidone.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ziprasidone.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Ziprasidone.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Ziprasidone.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Ziprasidone.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Ziprasidone.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Ziprasidone.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ziprasidone.]
[B02AB01, aprotinin, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Ziprasidone is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Ziprasidone.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Tilidine is combined with Ziprasidone.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Ziprasidone.]
[P01AB02, tinidazole, The metabolism of Tinidazole can be decreased when combined with Ziprasidone.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.]
[M02AX02, tolazoline, Ziprasidone may increase the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Ziprasidone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ziprasidone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Ziprasidone.]
[S01BA05, triamcinolone, The metabolism of Triamcinolone can be decreased when combined with Ziprasidone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Ziprasidone.]
[C03AA06, trichlormethiazide, Ziprasidone may increase the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziprasidone.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Ziprasidone.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ziprasidone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Ziprasidone.]
[R03BA07, mometasone, The metabolism of Ziprasidone can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Ziprasidone.]
[S01ED04, metipranolol, Ziprasidone may increase the antihypertensive activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ziprasidone.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Ziprasidone.]
[C02BA01, trimethaphan, Ziprasidone may increase the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Ziprasidone.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Ziprasidone.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ziprasidone.]
[A03BB01, butylscopolamine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Ziprasidone can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Ziprasidone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tropicamide.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Ziprasidone.]
[C09CA09, azilsartan medoxomil, Ziprasidone may increase the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Ziprasidone.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Ziprasidone.]
[S01AA05, tyrothricin, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Ziprasidone.]
[L02BX03, abiraterone, The metabolism of Abiraterone can be decreased when combined with Ziprasidone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.]
[J05AP03, boceprevir, The metabolism of Ziprasidone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Ziprasidone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ziprasidone.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ziprasidone.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ziprasidone.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Ziprasidone.]
[C08DA01, verapamil, Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Viloxazine is combined with Ziprasidone.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Ziprasidone.]
[C04AX07, vincamine, Ziprasidone may increase the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Ziprasidone.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Ziprasidone.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Ziprasidone.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Ziprasidone.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Ziprasidone is combined with Xenon.]
[C03BA10, xipamide, Ziprasidone may increase the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Ziprasidone.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ziprasidone.]
[J05AE02, indinavir, The metabolism of Ziprasidone can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziprasidone.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ziprasidone.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Ziprasidone.]
[R03DC01, zafirlukast, The metabolism of Ziprasidone can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Ziprasidone.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Ziprasidone.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Ziprasidone.]
[C07AB03, atenolol, Ziprasidone may increase the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ziprasidone.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Ziprasidone.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Ziprasidone.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Ziprasidone.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Ziprasidone.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Ziprasidone.]
[H02AB11, prednylidene, The metabolism of Prednylidene can be decreased when combined with Ziprasidone.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Ziprasidone.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Ziprasidone.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Ziprasidone.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ziprasidone.]
[V03AX03, cobicistat, The metabolism of Ziprasidone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Ziprasidone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ziprasidone.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Ziprasidone.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Ziprasidone.]
[H02AA01, aldosterone, The metabolism of Aldosterone can be decreased when combined with Ziprasidone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Ziprasidone.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Ziprasidone.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ziprasidone.]
[S01GA07, brimonidine, The risk or severity of adverse effects can be increased when Brimonidine is combined with Ziprasidone.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.]
[C08CA13, lercanidipine, Ziprasidone may increase the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Ziprasidone.]
[N06DA02, donepezil, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, The risk or severity of adverse effects can be increased when Perampanel is combined with Ziprasidone.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Ziprasidone.]
[N02CC03, zolmitriptan, The risk or severity of vasospastic reactions can be increased when Ziprasidone is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Ziprasidone.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Ziprasidone.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ziprasidone.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Ziprasidone.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ziprasidone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Ziprasidone.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Ziprasidone.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Ziprasidone.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Ziprasidone.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Ziprasidone can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Ziprasidone may increase the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ziprasidone.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Ziprasidone.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Ziprasidone is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Ziprasidone.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ziprasidone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ziprasidone.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ziprasidone.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Ziprasidone.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ziprasidone.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Ziprasidone.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Ziprasidone.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ziprasidone.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ziprasidone.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Ziprasidone is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ziprasidone.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ziprasidone.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Bepridil is combined with Ziprasidone.]
[C02KX05, riociguat, Ziprasidone may increase the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ziprasidone.]
[C02KX04, macitentan, Ziprasidone may increase the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Ziprasidone.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Ziprasidone.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be decreased when combined with Ziprasidone.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Ziprasidone.]
[J05AP05, simeprevir, The metabolism of Simeprevir can be decreased when combined with Ziprasidone.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ziprasidone.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ziprasidone.]
[C01CA27, droxidopa, Ziprasidone may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Ziprasidone.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Ziprasidone.]
[A16AA07, metreleptin, The metabolism of Ziprasidone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Ziprasidone can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Ziprasidone can be increased when combined with Formestane.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Ziprasidone.]
[A16AA06, betaine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The metabolism of Betamethasone can be decreased when combined with Ziprasidone.]
[S01ED02, betaxolol, The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ziprasidone.]
[C02CC01, bethanidine, Ziprasidone may increase the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Ziprasidone.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ziprasidone.]
[L04AC11, siltuximab, The metabolism of Ziprasidone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Ziprasidone.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Ziprasidone.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ziprasidone.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Ziprasidone.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Ziprasidone.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Ziprasidone.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ziprasidone.]
[S01EE02, unoprostone, Ziprasidone may increase the antihypertensive activities of Unoprostone.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Glycopyrronium.]
[N05CM19, suvorexant, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Ziprasidone.]
[J01XA05, oritavancin, The metabolism of Ziprasidone can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Ziprasidone.]
[V04CX03, methacholine, Ziprasidone may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Ziprasidone.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.]
[A06AH03, naloxegol, The metabolism of Naloxegol can be decreased when combined with Ziprasidone.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Ziprasidone.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Ziprasidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Ziprasidone.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ziprasidone.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Ziprasidone.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Ziprasidone.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dicoumarol.]
[N06AX11, mirtazapine, Ziprasidone may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Ziprasidone can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Ziprasidone.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ziprasidone.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Ziprasidone.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Ziprasidone.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Ziprasidone.]
[A03AA09, difemerine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tioclomarol.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Ziprasidone.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Ziprasidone.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Ziprasidone is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Ziprasidone.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Ziprasidone.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be decreased when combined with Ziprasidone.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Ziprasidone.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Ziprasidone.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Ziprasidone.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Ziprasidone is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Ziprasidone.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ziprasidone.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Ziprasidone.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Ziprasidone.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ziprasidone.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Ziprasidone.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Ziprasidone.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Ziprasidone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Ziprasidone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Ziprasidone.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Ziprasidone.]
[B01AC27, selexipag, Ziprasidone may increase the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ziprasidone.]
[M04AB05, lesinurad, The metabolism of Ziprasidone can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Ziprasidone.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Ziprasidone.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Ziprasidone.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Ziprasidone.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Ziprasidone.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Ziprasidone.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Ziprasidone.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ziprasidone.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Ziprasidone.]
[C08CA01, amlodipine, The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Ziprasidone.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Ziprasidone.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Ziprasidone.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziprasidone.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Ziprasidone.]
[N07BC01, buprenorphine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ziprasidone.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Ziprasidone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Ziprasidone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ziprasidone.]
[N06DA03, rivastigmine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Ziprasidone.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ziprasidone.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Ziprasidone.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ziprasidone.]
[S01GX07, azelastine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Ziprasidone.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Ziprasidone.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ziprasidone.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Ziprasidone.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Ziprasidone is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Ziprasidone.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Ziprasidone.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ziprasidone.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Ziprasidone.]
[C09AA07, benazepril, Ziprasidone may increase the antihypertensive activities of Benazepril.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Ziprasidone.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ziprasidone.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Ziprasidone.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Ziprasidone.]
[J05AE09, tipranavir, The metabolism of Ziprasidone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Ziprasidone.]
[L04AB02, infliximab, The metabolism of Ziprasidone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Ziprasidone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Ziprasidone.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Ziprasidone.]
[L04AC14, sarilumab, The metabolism of Ziprasidone can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ziprasidone.]
[D01AC10, bifonazole, The metabolism of Ziprasidone can be decreased when combined with Bifonazole.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Ziprasidone.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Ziprasidone.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ziprasidone.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Ziprasidone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Ziprasidone.]
[A02BX12, bismuth subnitrate, Ziprasidone may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, Ziprasidone may increase the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Ziprasidone.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Ziprasidone.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Ziprasidone.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Ziprasidone.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Ziprasidone.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Ziprasidone.]
[R03BA02, budesonide, The metabolism of Budesonide can be decreased when combined with Ziprasidone.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Ziprasidone.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Ziprasidone is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Ziprasidone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Ziprasidone.]
[J05AX18, letermovir, The metabolism of Ziprasidone can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Ziprasidone.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Ziprasidone.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ziprasidone.]
[N01BX04, capsaicin, The metabolism of Ziprasidone can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ziprasidone.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Ziprasidone.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ziprasidone.]
[C09AA01, captopril, Ziprasidone may increase the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Ziprasidone.]
[L02BB05, apalutamide, The metabolism of Ziprasidone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Ziprasidone.]
[A03AA03, camylofine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ziprasidone.]
[C07AG02, carvedilol, Ziprasidone may increase the antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Ziprasidone.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ziprasidone.]
[L04AA37, baricitinib, The metabolism of Baricitinib can be decreased when combined with Ziprasidone.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ziprasidone.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Ziprasidone.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Ziprasidone.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Ziprasidone.]
[J05AX24, tecovirimat, The metabolism of Ziprasidone can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Ziprasidone.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Ziprasidone.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Ziprasidone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Ziprasidone.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ziprasidone.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Ziprasidone.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Ziprasidone.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ziprasidone.]
[R06AA06, chlorphenoxamine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Ziprasidone is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ziprasidone.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziprasidone.]
[R03BB08, revefenacin, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Ziprasidone.]
[L04AA39, emapalumab, The metabolism of Ziprasidone can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Ziprasidone.]
[L01EX13, gilteritinib, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ziprasidone.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Ziprasidone.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Ziprasidone.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Ziprasidone.]
[C09AA08, cilazapril, Ziprasidone may increase the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Ziprasidone.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Ziprasidone.]
[S01ED05, carteolol, The risk or severity of QTc prolongation can be increased when Carteolol is combined with Ziprasidone.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Ziprasidone.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Ziprasidone.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Ziprasidone.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Ziprasidone.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Ziprasidone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Ziprasidone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Ziprasidone.]
[H02AB14, cloprednol, The metabolism of Ziprasidone can be increased when combined with Cloprednol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Ziprasidone.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Ziprasidone.]
[C09CA06, candesartan, Ziprasidone may increase the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Ziprasidone can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Ziprasidone can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Ziprasidone.]
[L01FX14, polatuzumab vedotin, The metabolism of Polatuzumab vedotin can be decreased when combined with Ziprasidone.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Ziprasidone.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Ziprasidone.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Ziprasidone.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Ziprasidone.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Ziprasidone.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ziprasidone.]
[L04AA44, upadacitinib, The metabolism of Upadacitinib can be decreased when combined with Ziprasidone.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Ziprasidone.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Ziprasidone.]
[N07XX11, pitolisant, The therapeutic efficacy of Pitolisant can be decreased when used in combination with Ziprasidone.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Ziprasidone.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Ziprasidone.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Ziprasidone.]
[C03AA09, cyclothiazide, Ziprasidone may increase the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Ziprasidone.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ziprasidone.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Ziprasidone.]
[S01EX02, dapiprazole, The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziprasidone.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Ziprasidone.]
[J01DB09, cephradine, The metabolism of Ziprasidone can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Ziprasidone.]
[G03DB05, demegestone, The metabolism of Demegestone can be decreased when combined with Ziprasidone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Ziprasidone.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Ziprasidone.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Ziprasidone.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Ziprasidone.]
[N03AX25, cenobamate, The serum concentration of Ziprasidone can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Ziprasidone.]
[L01FX13, enfortumab vedotin, The metabolism of Enfortumab vedotin can be decreased when combined with Ziprasidone.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ziprasidone.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Ziprasidone.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Ziprasidone.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Ziprasidone.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Ziprasidone.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Ziprasidone.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Ziprasidone.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Ziprasidone.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Ziprasidone.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ziprasidone.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Ziprasidone.]
[J05AE05, amprenavir, The metabolism of Ziprasidone can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Ziprasidone is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Ziprasidone.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Ziprasidone.]
[G03DB08, dienogest, The metabolism of Dienogest can be decreased when combined with Ziprasidone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Ziprasidone.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziprasidone.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Ziprasidone.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Ziprasidone.]
[L01XF03, bexarotene, The metabolism of Ziprasidone can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Ziprasidone is combined with Clevidipine.]
[C01BD07, dronedarone, Ziprasidone may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Ziprasidone.]
[J01FA13, dirithromycin, The metabolism of Ziprasidone can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Ziprasidone can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ziprasidone.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ziprasidone.]
[C02AA06, methoserpidine, Ziprasidone may increase the antihypertensive activities of Methoserpidine.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Ziprasidone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ziprasidone.]
[A03AA08, dihexyverine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Capmatinib can be decreased when combined with Ziprasidone.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Ziprasidone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Ziprasidone.]
[D07XB03, fluprednidene, The metabolism of Fluprednidene can be decreased when combined with Ziprasidone.]
[G04BD09, trospium, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Ziprasidone is combined with Droxicam.]
[L01EX19, ripretinib, The metabolism of Ripretinib can be decreased when combined with Ziprasidone.]
[L01EX22, selpercatinib, The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Ziprasidone.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Ziprasidone.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Ziprasidone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Ziprasidone.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Ziprasidone.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Ziprasidone.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Ziprasidone.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Ziprasidone.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Remimazolam is combined with Ziprasidone.]
[N07XX04, sodium oxybate, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Ziprasidone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ziprasidone is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Ziprasidone.]
[L01EX23, pralsetinib, The metabolism of Pralsetinib can be decreased when combined with Ziprasidone.]
[C03AA04, chlorothiazide, Ziprasidone may increase the antihypertensive activities of Chlorothiazide.]
[D01AE07, chlorphenesin, The risk or severity of adverse effects can be increased when Chlorphenesin is combined with Ziprasidone.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Ziprasidone.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Ziprasidone.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ziprasidone.]
[C03BA04, chlorthalidone, Ziprasidone may increase the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziprasidone.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Ziprasidone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Ziprasidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Ziprasidone is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Ziprasidone.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ziprasidone.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Ziprasidone.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Ziprasidone is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Ziprasidone is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Ziprasidone.]
[A16AX20, lonafarnib, The metabolism of Ziprasidone can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Ziprasidone.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Ziprasidone is combined with Naxitamab.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Ziprasidone.]
[P03AX07, abametapir, The serum concentration of Ziprasidone can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Tepotinib can be decreased when combined with Ziprasidone.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Ziprasidone.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Ziprasidone.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Ziprasidone.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Fenozolone.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Ziprasidone.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ziprasidone.]
[R03BA03, flunisolide, The metabolism of Ziprasidone can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Fluocinolone acetonide can be decreased when combined with Ziprasidone.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ziprasidone.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Ziprasidone.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Ziprasidone.]
[H04AA02, dasiglucagon, Ziprasidone may increase the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Ziprasidone can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ziprasidone.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Ziprasidone.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Ziprasidone.]
[L01XX73, sotorasib, The serum concentration of Ziprasidone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Ziprasidone.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ziprasidone.]
[L01XA01, cisplatin, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone.]
[J02AX07, ibrexafungerp, The metabolism of Ibrexafungerp can be decreased when combined with Ziprasidone.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Ziprasidone.]
[L04AA48, belumosudil, The metabolism of Belumosudil can be decreased when combined with Ziprasidone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Ziprasidone.]
[N02CD07, atogepant, The metabolism of Atogepant can be decreased when combined with Ziprasidone.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Ziprasidone.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Ziprasidone.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Ziprasidone is combined with Mefenamic acid.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Ziprasidone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Ziprasidone.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Ziprasidone.]
[L01EA06, asciminib, The metabolism of Asciminib can be decreased when combined with Ziprasidone.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Ziprasidone.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Ziprasidone.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Ziprasidone.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Ziprasidone.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Ziprasidone.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Ziprasidone.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ziprasidone.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Ziprasidone.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Ziprasidone.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Ziprasidone.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Ziprasidone.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Ziprasidone.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Ziprasidone.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Ziprasidone.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Ziprasidone.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Ziprasidone.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Ziprasidone.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ziprasidone.]
[L01XX77, adagrasib, The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Ziprasidone.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Ziprasidone.]
[L01EN04, futibatinib, The metabolism of Futibatinib can be decreased when combined with Ziprasidone.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Ziprasidone.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ziprasidone.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Ziprasidone.]
[H01AC08, somatrogon, The metabolism of Ziprasidone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Cocaine is combined with Ziprasidone.]
[M09AX11, palovarotene, The metabolism of Palovarotene can be decreased when combined with Ziprasidone.]
[C02KB01, metyrosine, Ziprasidone may increase the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Ziprasidone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Ziprasidone.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ziprasidone.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Ziprasidone.]
[A03AB10, hexocyclium, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Homatropine.]
[A03BB06, homatropine methylbromide, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ziprasidone.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Ziprasidone.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ziprasidone.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Ziprasidone.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Ziprasidone is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Ziprasidone.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ziprasidone.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Ziprasidone.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Ziprasidone.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ziprasidone.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Ziprasidone.]
[H01AX01, pegvisomant, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Ziprasidone.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ziprasidone.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Ziprasidone.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Ziprasidone.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Ziprasidone.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Ziprasidone.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ziprasidone.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Ziprasidone.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Ziprasidone.]
[S01EE04, travoprost, Ziprasidone may increase the antihypertensive activities of Travoprost.]
[S01EE03, bimatoprost, Ziprasidone may increase the antihypertensive activities of Bimatoprost.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Ziprasidone.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Ziprasidone.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ziprasidone.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ziprasidone.]
[S01BA03, cortisone, The metabolism of Ziprasidone can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ziprasidone.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Ziprasidone.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Ziprasidone is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Loratadine can be decreased when combined with Ziprasidone.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Ziprasidone.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Loxoprofen.]
[C09AA03, lisinopril, Ziprasidone may increase the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Ziprasidone.]
[C08CA11, manidipine, Ziprasidone may increase the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Ziprasidone.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Ziprasidone is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Ziprasidone.]
[H02AB15, meprednisone, The metabolism of Meprednisone can be decreased when combined with Ziprasidone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Ziprasidone.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ziprasidone.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Ziprasidone.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Ziprasidone is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ziprasidone.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Ziprasidone.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Ziprasidone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Ziprasidone.]
[C03AA07, cyclopenthiazide, Ziprasidone may increase the antihypertensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Ziprasidone.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclopentolate.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Ziprasidone.]
[J04AB01, cycloserine, Ziprasidone may increase the neurotoxic activities of Cycloserine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Ziprasidone.]
[N06BA07, modafinil, The metabolism of Ziprasidone can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ziprasidone.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ziprasidone.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Ziprasidone is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Ziprasidone can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Ziprasidone may increase the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Ziprasidone.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Ziprasidone.]
[G03XA01, danazol, The metabolism of Ziprasidone can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Ziprasidone.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Ziprasidone.]
[L01DB02, daunorubicin, The metabolism of Ziprasidone can be decreased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Ziprasidone.]
[C02CC04, debrisoquin, Ziprasidone may increase the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Ziprasidone.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Ziprasidone.]
[C07AB12, nebivolol, Ziprasidone may increase the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Nefazodone is combined with Ziprasidone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Ziprasidone.]
[C01DX16, nicorandil, Ziprasidone may increase the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Ziprasidone.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Ziprasidone.]
[C01CA23, theodrenaline, Ziprasidone may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ziprasidone.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Ziprasidone.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Normethadone is combined with Ziprasidone.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Ziprasidone.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Ziprasidone.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Ziprasidone is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Ziprasidone.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Ziprasidone.]
[C09XA02, aliskiren, Ziprasidone may increase the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ziprasidone.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Ziprasidone.]
[S03BA01, dexamethasone, The metabolism of Ziprasidone can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Ziprasidone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Ziprasidone.]
[G04BD04, oxybutynin, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Ziprasidone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Ziprasidone.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ziprasidone.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Ziprasidone.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ziprasidone.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ziprasidone.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Ziprasidone.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Ziprasidone.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Ziprasidone.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Ziprasidone.]
[V03AH01, diazoxide, Ziprasidone may increase the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Ziprasidone.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Ziprasidone.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ziprasidone.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Ziprasidone.]
[J01CF01, dicloxacillin, The metabolism of Ziprasidone can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ziprasidone.]
[A03AA07, dicyclomine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Ziprasidone may increase the neurotoxic activities of Didanosine.]
[C02DG01, pinacidil, Ziprasidone may increase the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Ziprasidone.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ziprasidone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Ziprasidone.]
[A03AB14, pipenzolate, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Ziprasidone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ziprasidone.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Ziprasidone.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Ziprasidone.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Ziprasidone.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Ziprasidone.]
[D07XC04, diflucortolone, The metabolism of Difluocortolone can be decreased when combined with Ziprasidone.]
[A03AB11, poldine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Ziprasidone is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ziprasidone.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ziprasidone.]
[C02DB01, dihydralazine, Ziprasidone may increase the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the vasoconstricting activities of Ziprasidone.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziprasidone.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Ziprasidone.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ziprasidone.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Ziprasidone.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Ziprasidone.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ziprasidone.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Ziprasidone.]
[R06AB03, dimethindene, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Ziprasidone.]
[M02AX03, dimethyl sulfoxide, The metabolism of Ziprasidone can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Ziprasidone.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Ziprasidone can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of adverse effects can be increased when Proparacaine is combined with Ziprasidone.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ziprasidone.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ziprasidone.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Ziprasidone.]
[C09AA06, quinapril, Ziprasidone may increase the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Ziprasidone.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Ziprasidone.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Ziprasidone.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Cisapride is combined with Ziprasidone.]
[C09AA05, ramipril, Ziprasidone may increase the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Ziprasidone.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Ziprasidone.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Ziprasidone.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ziprasidone.]
[N07AA03, distigmine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Ziprasidone.]
[S02AA12, rifamycin SV, The metabolism of Ziprasidone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ziprasidone can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Ziprasidone.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Ziprasidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ziprasidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziprasidone.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ziprasidone.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ziprasidone.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be decreased when combined with Ziprasidone.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Ziprasidone.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ziprasidone.]
[J05AE07, fosamprenavir, The metabolism of Fosamprenavir can be decreased when combined with Ziprasidone.]
[G04BE08, tadalafil, Ziprasidone may increase the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ziprasidone is combined with Ketorolac.]
[C02KX02, ambrisentan, Ziprasidone may increase the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Ziprasidone.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Ziprasidone is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ziprasidone.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Ziprasidone.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ziprasidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Ziprasidone is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ziprasidone.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Ziprasidone is combined with Doxapram.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Ziprasidone.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Ziprasidone.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Ziprasidone.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ziprasidone.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Sertraline is combined with Ziprasidone.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Ziprasidone.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ziprasidone.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Sibutramine is combined with Ziprasidone.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Ziprasidone.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ziprasidone.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Ziprasidone.]
[C09AA11, spirapril, Ziprasidone may increase the antihypertensive activities of Spirapril.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Ziprasidone.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Ziprasidone.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone.]
[V04CX07, edrophonium, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Ziprasidone.]
[H01AA01, corticotropin, The metabolism of Corticotropin can be decreased when combined with Ziprasidone.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Ziprasidone.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Ziprasidone is combined with Tenoxicam.]
[G04CA03, terazosin, Ziprasidone may increase the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Ziprasidone.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Terodiline is combined with Ziprasidone.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Ziprasidone.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Ziprasidone.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Ziprasidone.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Ziprasidone.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Ziprasidone.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Ziprasidone.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Ziprasidone.]
[C09AA02, enalapril, Ziprasidone may increase the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Ziprasidone.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Ziprasidone.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Toloxatone is combined with Ziprasidone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ziprasidone.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Ziprasidone is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Ziprasidone.]
[C03CA04, torsemide, Ziprasidone may increase the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Ziprasidone is combined with Tramazoline.]
[C09AA10, trandolapril, Ziprasidone may increase the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Ziprasidone.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ziprasidone.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Ziprasidone.]
[A03AB08, tridihexethyl, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Ziprasidone.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ziprasidone.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Ziprasidone.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Ziprasidone.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Ziprasidone.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Ziprasidone.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ziprasidone.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Ziprasidone.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Ziprasidone.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Ziprasidone.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Ziprasidone.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ziprasidone.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Ziprasidone.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Ziprasidone.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Ziprasidone is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Ziprasidone.]
[C09AA15, zofenopril, Ziprasidone may increase the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Ziprasidone.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Ziprasidone.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ziprasidone.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zopiclone is combined with Ziprasidone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Ziprasidone.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ziprasidone.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Ziprasidone.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Ziprasidone.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Ziprasidone.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ziprasidone.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Ziprasidone.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Ziprasidone.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Ziprasidone.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Ziprasidone.]
[L01XX11, estramustine, The metabolism of Estramustine can be decreased when combined with Ziprasidone.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Ziprasidone.]
[J04AK02, ethambutol, The metabolism of Ziprasidone can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.]
[R03BA05, fluticasone, The metabolism of Ziprasidone can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Ziprasidone.]
[C01CA15, gepefrine, Gepefrine may decrease the sedative and stimulatory activities of Ziprasidone.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Ziprasidone.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Ziprasidone.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Ziprasidone.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ziprasidone.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Ziprasidone.]
[N01BX01, ethyl chloride, The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Ziprasidone.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Ziprasidone.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziprasidone.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Ziprasidone.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Ziprasidone.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Ziprasidone.]
[N05AE03, sertindole, The risk or severity of QTc prolongation can be increased when Sertindole is combined with Ziprasidone.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ziprasidone.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Ziprasidone.]
[A02BA04, nizatidine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Ziprasidone.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Astemizole is combined with Ziprasidone.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Ziprasidone.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Ziprasidone.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziprasidone.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Ziprasidone.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Ziprasidone.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ziprasidone.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Ziprasidone.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Ziprasidone.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Ziprasidone.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Ziprasidone.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Ziprasidone.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Ziprasidone.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Ziprasidone.]
[G04BD02, flavoxate, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ziprasidone.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Ziprasidone is combined with Floctafenine.]
[J01CF05, floxacillin, The metabolism of Ziprasidone can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ziprasidone.]
[H02AA02, fludrocortisone, The metabolism of Fludrocortisone can be decreased when combined with Ziprasidone.]
[D07XB01, flumethasone, The metabolism of Flumethasone can be decreased when combined with Ziprasidone.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Ziprasidone.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ziprasidone.]
[D07AC08, fluocinonide, The metabolism of Fluocinonide can be decreased when combined with Ziprasidone.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Ziprasidone.]
[H02AB03, fluocortolone, The metabolism of Fluocortolone can be decreased when combined with Ziprasidone.]
[V03AZ01, ethanol, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ziprasidone.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ziprasidone.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Ziprasidone.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziprasidone.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Ziprasidone.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Ziprasidone.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Ziprasidone.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ziprasidone.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Ziprasidone.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Ziprasidone.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Ziprasidone.]
[J05AE10, darunavir, The metabolism of Ziprasidone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Ziprasidone may increase the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Ziprasidone is combined with Eszopiclone.]
[N05AL05, amisulpride, Ziprasidone may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ziprasidone.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Ziprasidone.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Ziprasidone.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Ziprasidone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Ziprasidone.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Ziprasidone.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ziprasidone.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ziprasidone.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ziprasidone.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone.]
[J05AG04, etravirine, The metabolism of Ziprasidone can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ziprasidone.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be decreased when combined with Ziprasidone.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Ziprasidone.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Ziprasidone.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Ziprasidone.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Ziprasidone.]
[H04AA01, glucagon, Ziprasidone may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ziprasidone.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Ziprasidone.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Ziprasidone.]
[C05AE01, nitroglycerin, Ziprasidone may increase the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Ziprasidone.]
[C02CA04, doxazosin, Ziprasidone may increase the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ziprasidone.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ziprasidone.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluindione.]
[C09AA09, fosinopril, Ziprasidone may increase the antihypertensive activities of Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Ziprasidone can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Ziprasidone may increase the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ziprasidone.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Ziprasidone.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ziprasidone.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Ziprasidone.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Ziprasidone.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Ziprasidone.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ziprasidone.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Ziprasidone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Ziprasidone.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Ziprasidone.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Ziprasidone.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Ziprasidone.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Ziprasidone.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ziprasidone.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Ziprasidone.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ziprasidone.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Ziprasidone.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Ziprasidone.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Ziprasidone.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Ziprasidone is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Ziprasidone.]
[C09AA04, perindopril, Ziprasidone may increase the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Ziprasidone may increase the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ziprasidone.]
[R05DA03, hydrocodone, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.]
[C03AA02, hydroflumethiazide, Ziprasidone may increase the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ziprasidone.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Ziprasidone.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Ziprasidone.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Rifabutin can be decreased when combined with Ziprasidone.]
[C02AC06, rilmenidine, Ziprasidone may increase the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Ziprasidone.]
[B05CB02, sodium citrate, Ziprasidone may increase the neurotoxic activities of Sodium citrate.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Ziprasidone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Ziprasidone.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziprasidone.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ziprasidone.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ziprasidone.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Ziprasidone.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ziprasidone.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ziprasidone.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Ziprasidone is combined with Indomethacin.]
[C02CA02, indoramin, Ziprasidone may increase the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Milnacipran is combined with Ziprasidone.]
[A03AA30, piperidolate, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Ziprasidone.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ziprasidone.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Ziprasidone.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Ziprasidone.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ziprasidone.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Ziprasidone.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Ziprasidone.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Ziprasidone.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Ziprasidone.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Ziprasidone.]
[J05AF04, stavudine, Ziprasidone may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Ziprasidone.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Ziprasidone.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Ziprasidone.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.]
[S01EC03, dorzolamide, Ziprasidone may increase the antihypertensive activities of Dorzolamide.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Ziprasidone.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Ziprasidone.]
[C09AA16, imidapril, Ziprasidone may increase the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ziprasidone.]
[S01EB07, isoflurophate, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Ziprasidone.]
[J04AC01, isoniazid, The metabolism of Ziprasidone can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Ziprasidone.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Ziprasidone.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Ziprasidone.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Ziprasidone.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Ziprasidone.]
[L04AC07, tocilizumab, The metabolism of Ziprasidone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Ziprasidone.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Ziprasidone.]
[H02CA04, levoketoconazole, The risk or severity of QTc prolongation can be increased when Levoketoconazole is combined with Ziprasidone.]
[J02AB02, ketoconazole, The serum concentration of Ziprasidone can be increased when it is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ziprasidone.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Ziprasidone can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Ziprasidone can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Ziprasidone.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Ziprasidone.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Rotigotine is combined with Ziprasidone.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Ziprasidone.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Ziprasidone is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Ziprasidone may increase the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ziprasidone.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Ziprasidone.]
[C02AA05, deserpidine, Ziprasidone may increase the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Ziprasidone.]
[N07AA30, ambenonium, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ziprasidone.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Ziprasidone.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Ziprasidone.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Ziprasidone.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ziprasidone.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Ziprasidone.]
[J01FF02, lincomycin, Ziprasidone may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Ziprasidone can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Ziprasidone.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Ziprasidone.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Ziprasidone.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Ziprasidone.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Ziprasidone.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Ziprasidone.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Ziprasidone.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Ziprasidone.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ziprasidone.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ziprasidone.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Ziprasidone can be increased when used in combination with Magnesium sulfate.]
[P03AX03, malathion, The risk or severity of QTc prolongation can be increased when Malathion is combined with Ziprasidone.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Ziprasidone.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ziprasidone.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Ziprasidone.]
[C02BB01, mecamylamine, Ziprasidone may increase the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Ziprasidone.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Ziprasidone is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Ziprasidone.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Ziprasidone.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Ziprasidone.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Ziprasidone.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Ziprasidone.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Ziprasidone.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Ziprasidone.]
[M03BX06, mephenesin, The risk or severity of adverse effects can be increased when Mephenesin is combined with Ziprasidone.]
[C01CA11, mephentermine, Mephentermine may decrease the sedative and stimulatory activities of Ziprasidone.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Ziprasidone.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ziprasidone.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Ziprasidone.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Ziprasidone.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Meptazinol is combined with Ziprasidone.]
[L02BG01, aminoglutethimide, The metabolism of Ziprasidone can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Ziprasidone.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ziprasidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Ziprasidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ziprasidone.]
[H01CB03, lanreotide, The metabolism of Ziprasidone can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Ziprasidone.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Ziprasidone.]
[A03AB07, methantheline, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ziprasidone.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Ziprasidone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Ziprasidone.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Ziprasidone.]
[H03BB02, methimazole, The metabolism of Ziprasidone can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziprasidone.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Ziprasidone.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Ziprasidone.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Ziprasidone.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ziprasidone.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Ziprasidone.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziprasidone.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Ziprasidone.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Ziprasidone.]
[C02AB01, methyldopa, Ziprasidone may increase the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Ziprasidone may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the vasoconstricting activities of Ziprasidone.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Ziprasidone.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Ziprasidone.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Ziprasidone.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Ziprasidone.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.]
[C03BA08, metolazone, Ziprasidone may increase the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Ziprasidone may increase the antihypertensive activities of Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Ziprasidone.]
[V04CD01, metyrapone, The metabolism of Ziprasidone can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Ziprasidone.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Ziprasidone.]
[S02AA13, miconazole, The metabolism of Ziprasidone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Ziprasidone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Ziprasidone.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Ziprasidone.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Ziprasidone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Ziprasidone.]
[C09CA03, valsartan, Ziprasidone may increase the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.]
[D11AX01, minoxidil, Ziprasidone may increase the antihypertensive activities of Minoxidil.]
[J01FA11, miocamycin, The metabolism of Ziprasidone can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Ziprasidone can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Ziprasidone.]
[L03AC01, aldesleukin, The metabolism of Ziprasidone can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Ziprasidone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Ziprasidone.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Ziprasidone.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Ziprasidone.]
[L04AB05, certolizumab pegol, The metabolism of Ziprasidone can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Ziprasidone.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Ziprasidone.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Ziprasidone.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ziprasidone.]
[G04CA04, silodosin, The metabolism of Silodosin can be decreased when combined with Ziprasidone.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ipratropium.]
[G03XC01, raloxifene, The metabolism of Ziprasidone can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ziprasidone.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ziprasidone.]
[C07AA12, nadolol, Ziprasidone may increase the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Ziprasidone.]
[J01CF06, nafcillin, The metabolism of Ziprasidone can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Ziprasidone.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ziprasidone.]
[V03AB15, naloxone, The metabolism of Ziprasidone can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Ziprasidone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Ziprasidone.]
[N06BA01, amphetamine, Amphetamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Ziprasidone is combined with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Ziprasidone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Duloxetine is combined with Ziprasidone.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Ziprasidone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Ziprasidone.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Ziprasidone.]
[S03AA01, neomycin, Ziprasidone may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Ziprasidone.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ziprasidone.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Ziprasidone.]
[S01EB06, neostigmine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Ziprasidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ziprasidone.]
[C09CA07, telmisartan, Ziprasidone may increase the antihypertensive activities of Telmisartan.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Ziprasidone.]
[C10AD02, niacin, The metabolism of Ziprasidone can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Ziprasidone.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ziprasidone.]
[C04AE02, nicergoline, Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicergoline.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Ziprasidone.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Ziprasidone is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Ziprasidone.]
[C08CA07, nisoldipine, Ziprasidone may increase the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziprasidone.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Ziprasidone.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ziprasidone.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Ziprasidone.]
[C02DD01, nitroprusside, Ziprasidone may increase the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ziprasidone.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Ziprasidone.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Ziprasidone.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Ziprasidone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ziprasidone.]
[C02KX01, bosentan, Ziprasidone may increase the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ziprasidone.]
[R05DA07, noscapine, The metabolism of Ziprasidone can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Ziprasidone.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ziprasidone.]
[J01FA05, oleandomycin, The metabolism of Ziprasidone can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Ziprasidone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Ziprasidone.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Ziprasidone.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Opium is combined with Ziprasidone.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Ziprasidone.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone.]
[G04CA02, tamsulosin, Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Ziprasidone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Ziprasidone.]
[C07AA02, oxprenolol, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Ziprasidone.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Ziprasidone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Ziprasidone.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Ziprasidone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziprasidone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Ziprasidone.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Asenapine is combined with Ziprasidone.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Ziprasidone.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be decreased when combined with Ziprasidone.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ziprasidone.]
[N05CC05, paraldehyde, The risk or severity of adverse effects can be increased when Paraldehyde is combined with Ziprasidone.]
[H02AB05, paramethasone, The metabolism of Paramethasone can be decreased when combined with Ziprasidone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Ziprasidone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ziprasidone.]
[G04BD11, fesoterodine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Ziprasidone.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Ziprasidone.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Ziprasidone.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ziprasidone.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Ziprasidone.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Ziprasidone.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Ziprasidone.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ziprasidone.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Ziprasidone.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Phenazocine is combined with Ziprasidone.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Ziprasidone.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ziprasidone.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ziprasidone.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Ziprasidone.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Phenoperidine is combined with Ziprasidone.]
[C04AX02, phenoxybenzamine, Ziprasidone may increase the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Ziprasidone.]
[A08AA01, phentermine, Phentermine may decrease the sedative and stimulatory activities of Ziprasidone.]
[V03AB36, phentolamine, Ziprasidone may increase the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Ziprasidone can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Ziprasidone.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Ziprasidone.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Ziprasidone.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Ziprasidone.]
[L04AB06, golimumab, The metabolism of Ziprasidone can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Ziprasidone.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ziprasidone.]
[V03AB19, physostigmine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Physostigmine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Ziprasidone.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Ziprasidone.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Pimozide is combined with Ziprasidone.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Ziprasidone.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Ziprasidone.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Ziprasidone.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziprasidone.]
[C09CA02, eprosartan, Ziprasidone may increase the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Ziprasidone.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Piritramide is combined with Ziprasidone.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Ziprasidone is combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Ziprasidone.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Ziprasidone.]
[J05AG02, delavirdine, The metabolism of Ziprasidone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Ziprasidone may increase the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Ziprasidone.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziprasidone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Ziprasidone.]
[L04AC08, canakinumab, The metabolism of Ziprasidone can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Ziprasidone may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Ziprasidone may increase the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ziprasidone.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ziprasidone.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Ziprasidone is combined with Potassium chloride.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ziprasidone.]
[C07AB01, practolol, Ziprasidone may increase the antihypertensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Ziprasidone.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Ziprasidone.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Ziprasidone.]
[C02CA01, prazosin, Ziprasidone may increase the antihypertensive activities of Prazosin.]
[S03BA02, prednisolone, The metabolism of Prednisolone can be decreased when combined with Ziprasidone.]
[H02AB07, prednisone, The metabolism of Prednisone can be decreased when combined with Ziprasidone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Ziprasidone.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Ziprasidone.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Ziprasidone.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Ziprasidone.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Ziprasidone.]
[M04AB01, probenecid, The metabolism of Ziprasidone can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Ziprasidone.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ziprasidone.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Ziprasidone.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Ziprasidone.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ziprasidone.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Ziprasidone.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Ziprasidone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Ziprasidone.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Ziprasidone.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ziprasidone.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Ziprasidone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Ziprasidone.]
[A03AB05, propantheline, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Ziprasidone.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Ziprasidone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ziprasidone.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ziprasidone.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziprasidone.]
[C07AA05, propranolol, The risk or severity of QTc prolongation can be increased when Propranolol is combined with Ziprasidone.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.]
[B01AC09, epoprostenol, Ziprasidone may increase the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Ziprasidone.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ziprasidone.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the sedative and stimulatory activities of Ziprasidone.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ziprasidone.]
[S01EB03, ecothiopate, The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Ziprasidone.]
[A03AB15, diphemanil, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Ziprasidone.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Ziprasidone.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Ziprasidone.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Ziprasidone.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Ziprasidone.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ziprasidone.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Ziprasidone.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Ziprasidone.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Ziprasidone.]
[C02AA01, rescinnamine, Ziprasidone may increase the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.]
[J04AB02, rifampin, The metabolism of Ziprasidone can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Ziprasidone.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Ziprasidone.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Ziprasidone.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Ziprasidone.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Ziprasidone is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Ziprasidone is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ziprasidone.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Ziprasidone.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Ziprasidone.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Ziprasidone.]
[H01CB01, somatostatin, The metabolism of Ziprasidone can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Ziprasidone.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ziprasidone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ziprasidone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Ziprasidone.]
